Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Earnings for Bristol-Myers Squibb Company (BMY)
Earnings in 2023 (TTM): $8.44 B
According to Bristol-Myers Squibb Company's latest financial reports the company's current earnings (TTM) are $8.44 B. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Bristol-Myers Squibb Company
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $8.44 B | $8.03 B |
| 2022 | $7.71 B | $6.33 B |
| 2021 | $8.1 B | $6.99 B |
| 2020 | $-6,871,000,000 | $-8,995,000,000 |
| 2019 | $4.98 B | $3.44 B |
| 2018 | $6.01 B | $4.95 B |
| 2017 | $5.13 B | $1.01 B |
| 2016 | $5.92 B | $4.46 B |
| 2015 | $2.17 B | $1.62 B |
| 2014 | $2.38 B | $2 B |
| 2013 | $2.89 B | $2.56 B |
| 2012 | $2.34 B | $1.96 B |
| 2011 | $6.98 B | $3.71 B |
| 2010 | $6.07 B | $3.1 B |
| 2009 | $5.6 B | $10.61 B |
| 2008 | $5.47 B | $5.25 B |
| 2007 | $3.53 B | $2.17 B |
| 2006 | $2.64 B | $1.59 B |
| 2005 | $4.52 B | $3 B |
| 2004 | $4.42 B | $2.39 B |
| 2003 | $4.69 B | $3.11 B |
| 2002 | $2.65 B | $2.07 B |
| 2001 | $2.9 B | $5.25 B |
| 2000 | $5.48 B | $4.71 B |
| 1999 | $5.77 B | $4.17 B |
| 1998 | $4.27 B | $3.14 B |
| 1997 | $4.48 B | $3.21 B |
| 1996 | $4.01 B | $2.85 B |
| 1995 | $2.4 B | $1.81 B |
| 1994 | $2.56 B | $1.84 B |
| 1993 | $2.57 B | $1.96 B |
| 1992 | $1.99 B | $1.96 B |
| 1991 | $2.89 B | $2.06 B |
| 1990 | $2.52 B | $1.75 B |
| 1989 | $1.28 B | $747 M |
| 1988 | $1.89 B | $1.25 B |
| 1987 | $1.63 B | $1.07 B |